Consequently, the enhanced response to PD-1 blockade in patients supplemented with a live biotherapeutic CBM588 may be supported by a greater accumulation of immunosuppressive Rorγt+ Treg to the large intestine that may contribute to a more immunogenic reprogramming of the tumor-draining lymph node that are strategically positioned for draining the tumor. This evidence concerns the gene PDCD1 and neoplasm.